利索-全球专利检索

  1. Login
  2. Sign Up

Search Results

17 records (took 0.019 seconds)

    Rare molecule detection
    3.
    发明授权
    Rare molecule detection 有权

    公开(公告)号：US10809264B2

    公开(公告)日：2020-10-20

    申请号：US15314860

    申请日：2015-05-29

    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.

    Inventor： Michael Pugia ,  Julia Philip ,  Karen Marfurt

    IPC: G01N33/58 ,  G01N33/68 ,  G01N1/40

    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.

    Rare cell concentration
    7.
    发明授权
    Rare cell concentration 有权

    公开(公告)号：US10444240B2

    公开(公告)日：2019-10-15

    申请号：US14780937

    申请日：2014-03-26

    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.

    Inventor： Michael Pugia

    IPC: G01N33/574 ,  G01N33/50 ,  G01N33/569 ,  G01N33/86 ,  G01N33/53 ,  C12Q1/56

    Abstract: A ratio of rare cells to non-rare cells in a blood sample suspected of containing rare cells and non-rare cells is enhanced. A treated blood sample is prepared by providing in combination the blood sample, a platelet deactivation agent, a fibrin-formation-arresting agent and fibrin in an amount sufficient to cause a predetermined level of agglutination of the rare cells. The treated blood sample is then contacted with a porous matrix such that agglutinated rare cells are preferentially retained on the porous matrix. The rare cells may then be identified.

    RARE MOLECULE DETECTION
    8.
    发明申请
    RARE MOLECULE DETECTION 审中-公开

    公开(公告)号：US20170102390A1

    公开(公告)日：2017-04-13

    申请号：US15314860

    申请日：2015-05-29

    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.

    Inventor： Michael Pugia ,  Julia Philip ,  Karen Marfurt

    IPC: G01N33/58

    Abstract: A concentrated sample having enhanced concentration of the one or more different populations of target rare molecules is incubated with, for each different population of target rare molecules, a particulate or non-particulate affinity agent that comprises a specific binding partner that is specific for and binds to a target rare molecule. The affinity agent comprises a mass spectrometry (MS) label precursor or a first alteration agent, which either facilitates the formation of an MS label from the MS label precursor or releases an entity that comprises the MS label precursor from the affinity agent. The MS label corresponds to one of the populations of target rare molecules. A second alteration agent is employed if the first alteration agent does not facilitate the formation of an MS label from the MS label precursor. MS analysis is used to determine each different MS label.

    CELL-BASED CONTROL AND METHOD
    9.
    发明申请
    CELL-BASED CONTROL AND METHOD 审中-公开
    基于细胞的控制和方法

    公开(公告)号：US20160178614A1

    公开(公告)日：2016-06-23

    申请号：US14909449

    申请日：2014-07-30

    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.

    Inventor： Michael Pugia ,  Karen L. Marfurt

    IPC: G01N33/50

    CPC classification number: G01N33/5023 ,  C12N5/0602 ,  G01N33/5005 ,  G01N33/5044 ,  G01N33/5064 ,  G01N33/574 ,  G01N33/96 ,  G01N2001/2893

    Abstract: Control cells include a stable intact cell and, on the surface of the stable intact cell, a plurality of different antigens. Each of the different antigens corresponds to an antigen of interest. The control cells are employed in methods of evaluating the efficacy of a biological procedure performed on a sample. The method comprises conducting the biological procedure in the presence of the control cells. The control cells are examined to determine the efficacy of the biological procedure.

    Abstract translation: 对照细胞包括稳定的完整细胞，并且在稳定的完整细胞的表面上具有多种不同的抗原。 每种不同的抗原对应于感兴趣的抗原。 对照细胞用于评估对样品进行的生物学过程的功效的方法。 该方法包括在存在对照细胞的情况下进行生物学过程。 检查对照细胞以确定生物学程序的功效。

    Feedback control for improved rare cell detection
    10.
    发明授权
    Feedback control for improved rare cell detection 审中-公开

    公开(公告)号：US10670500B2

    公开(公告)日：2020-06-02

    申请号：US15322855

    申请日：2015-07-02

    Applicant: SIEMENS HEALTHCARE DIAGNOSTICS INC.

    Inventor： Michael Pugia ,  Julia Philip ,  Karen Marfurt

    IPC: G01N1/00 ,  G01N1/40 ,  G01N15/02 ,  G01N35/00

    Abstract: There is provided a system (10) and method (100) for improving ICC and/or ISH rare cell detection by lowering background noise and providing enhanced detection of rare cells (15). In an embodiment, background noise for an ICC and/or an ISH rare cell detection assay is reduced and rare cell signaling is enhanced via feedback control. To accomplish the feedback control, an electronic control circuit (24) can direct a fluid delivery apparatus (18) to add an adjustment amount to account for fluid loss in the system (10) when fluid loss is indicated.

Patent Agency Ranking